首页> 外文期刊>Patient Preference and Adherence >Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII
【24h】

Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII

机译:用图坦柯克阿尔法聚乙二醇(N8-GP)治疗的血友病A患者的健康相关生活质量和治疗满意度:新型重组延长的半衰期FVIII

获取原文
           

摘要

Background: Prophylactic treatment regimens lead to improvements in health-related quality-of-life (HRQoL) among individuals with hemophilia. Turoctocog alfa pegol (N8-GP) provides the benefit of extending the duration of protection from bleeding and reducing the number of injections, which is expected to impact HRQoL and treatment satisfaction (TS). Aim: To investigate the HRQoL and TS of patients with severe hemophilia A from two phase III trials evaluating the safety and efficacy of N8-GP. Methods: HRQoL was assessed using the Haemo-QoL (reported by children and their parents) and Haem-A-QoL (reported by adults). TS was assessed using Hemo-Sat. Domain and total scores for all questionnaires ranged from 0 to 100, with lower scores indicating a better HRQoL or TS. A negative change in score indicates an improvement in HRQoL/TS. Results: Mean changes in HRQoL scores were reported for 14 children aged 4–7 years, 21 children aged 8–11?years, 10 adolescents aged 13–16?years, and 163 adults (17?years and above). Mean changes in children/adolescents-reported Haemo-QoL total score were -14.0 for ages 4–7?years, -3.6 for ages 8–11?years, and -0.1 for ages 13–16?years. Mean changes in parent-reported Haemo-QoL total scores were -11.5 for 4–7?years, -8.6 for ages 8–11?years, and -4.0 for 13–16?years. Adults’ mean change in Haem-A-QoL total score was -3.1 for those receiving on-demand treatment and -2.3 for those receiving prophylaxis treatment. High levels of TS with N8-GP were reported by parents of children/adolescents and the adults at the end of the trial. Conclusion: While most patients reported a relatively good baseline HRQoL when entering the respective trials, the HRQoL of patients was either maintained or further improved when treated with N8-GP. Adults and parents of children and adolescents reported a high level of treatment satisfaction with N8-GP.
机译:背景:预防性治疗方案可改善血友病患者健康相关的生活质量(HRQoL)。 Turoctocog alfa pegol(N8-GP)的好处是延长了防止出血的持续时间并减少了注射次数,这有望影响HRQoL和治疗满意度(TS)。目的:从两项评估N8-GP的安全性和有效性的III期临床试验中,研究重度A型血友病患者的HRQoL和TS。方法:使用Haemo-QoL(由儿童及其父母报告)和Haem-A-QoL(由成人报告)评估HRQoL。使用Hemo-Sat评估TS。所有问卷的领域和总得分范围从0到100,得分较低表示HRQoL或TS更好。分数的负变化表示HRQoL / TS有所改善。结果:报告了HRQoL得分的平均变化,包括14位4-7岁的儿童,21位8-11岁的儿童,10位13-16岁的青少年以及163位成人(17岁及以上)。儿童/青少年报告的Haemo-QoL总得分的平均变化在4-7岁之间为-14.0,在8-11岁之间为-3.6,而在13-16岁之间为-0.1。父母报告的Haemo-QoL总得分的平均变化为4-7岁年为-11.5,8-11岁年龄为-8.6,而13-16岁年龄为-4.0。接受按需治疗的成年人的平均Haem-A-QoL总得分变化为-3.1,接受预防性治疗的成年人为-2.3。在试验结束时,儿童/青少年的父母和成年人报告了N8-GP的高水平TS。结论:尽管大多数患者在进入各自的试验中均报告了相对较好的基线HRQoL,但使用N8-GP治疗后患者的HRQoL得以维持或进一步改善。成人和儿童及青少年的父母对N8-GP的治疗满意度很高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号